Key result
FFR-guided complete revascularization reduces major events ~24% versus infarct-artery only treatment.
Why the study?
The long-term outcomes of complete revascularization in STEMI and multivessel disease were unknown.
Does FFR-guided complete revascularization reduce the composite of all-cause mortality, recurrent myocardial infarction, or any revascularization in patients with STEMI and multivessel disease compared to infarct-related artery only treatment?
RCT (n=627)
Does FFR-guided complete revascularization reduce the composite of all-cause mortality, recurrent myocardial infarction, or any revascularization in patients with STEMI and multivessel disease compared to infarct-related artery only treatment?
At 10-year follow-up, FFR-guided complete revascularization in STEMI patients with multivessel disease reduced the composite of death, MI, or revascularization, driven entirely by fewer subsequent revascularizations.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is a benefit with complete revascularization, and it is a durable benefit.”
Supports FFR-guided complete revascularization in multivessel STEMI; confirms durable benefit to 10 years without late catch-up.
BACKGROUND The long-term outcomes of complete revascularization in ST-segment elevation myocardial infarction (STEMI) and multivessel disease is unknown. OBJECTIVES To investigate the 10-year clinical outcomes including repeated events of fractional flow reserve (FFR)-guided complete revascularization versus treatment of the infarct-related artery only in STEMI. METHODS This 10-year follow-up study of the DANAMI-3-PRIMULTI trial included patients with STEMI and ≥1 angiographically significant non-infarct-related lesion, randomized to FFR-guided complete revascularization or infarct-related artery only after the index procedure. As the original trial, the primary outcome was a composite of all-cause mortality, recurrent myocardial infarction, or any revascularization. Repeated events of revascularization and myocardial infarction were analyzed. RESULTS Of 627 included patients, 313 were randomized to infarct-related artery only and 314 to complete revascularization. After 10 years, complete revascularization reduced the risk of the primary outcome (hazard ratio 0.76 (95% confidence interval (CI), 0.60-0.94) p=0.014). In the infarct-related artery only group, 78 (25%) died vs. 74 (24%) in the complete revascularization group. Complete revascularization reduced any revascularization compared with infarct-related artery only (odds ratio. 0.62 (95% CI: 0.44-0.89)). There was no difference in recurrent myocardial infarction (odds ratio, 0.90 (95% CI, 0.60-1.35)). The mean cumulative number of events were 76/100 persons (95% CI, 66-88) in the infarct-related artery only group vs. 63 events/100 persons (95% CI, 54-73) in the complete revascularization group (absolute reduction, 13% (95% CI, -1%-28%)). CONCLUSIONS FFR-guided complete revascularization reduced future and repeated events compared with infarct-related artery only after 10 years. The risk was mainly driven by revascularization, with no reduction in myocardial infarctions or death.
No takes yet. Share an insight, caveat, or question.
Beske et al. (2025) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) and multivessel disease (n=627). FFR-guided complete revascularization vs. Infarct-related artery only treatment was evaluated on Composite of all-cause mortality, recurrent myocardial infarction, or any revascularization (HR 0.76, 95% CI 0.60-0.94, p=0.014). FFR-guided complete revascularization reduced the composite of mortality, recurrent MI, or revascularization compared to infarct-artery only treatment at 10 years.
Synapse has enriched 10 related papers. Consider them for comparative context: